Sessions

*Please scroll down for more information*
Tuberculosis (TB) therapeutics research is experiencing a renaissance with an increasing number of new compounds, innovative tools and strategies undergoing evaluation as part of novel regimen development. This is welcome progress as the field seeks to address the long durations of treatment, toxicities, drug–drug interactions and high costs of current therapies. This session will highlight the potential of therapeutic vaccines, innovative tools for regimen development and genomic discoveries with relevance to development of host-directed therapies for curing TB.

16:30 - 16:32: Session introduction


16:32 - 16:40: TBS-OA-13-An empirical modeling approach for regimen development: How to build a winning team.

Natasha Strydom

16:40 - 16:48: TBS-OA-14-The role of respiratory microbiome in early bactericidal activity of anti-tuberculosis therapy and treatment outcome

Wilber Sabiiti

16:48 - 16:56: TBS-OA-15-In silico assessment of adaptive trial design for TB regimen development

Vincent Chang

16:56 - 17:04: TBS-OA-16-Translational platform for predicting clinical outcomes for new combination regimens using pre-clinical and phase I​ data

Qianwen Wang

17:04 - 17:12: Live Q&A